GlassScriptPhysician profile
Clint E Gonzales
NPI 1528030780
$5,795.47
in general payments reported to CMS, 2019-2025
27 companies · $730 in 2025
The $730 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $353 · 2021: $1,287 · 2022: $1,056 · 2023: $825 · 2024: $699 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $924.37 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $843.86 | 2019-2025 | Cequa |
| Abbvie INC. | $586.43 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $474.02 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Oyster Point Pharma, INC. | $461.89 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $413.90 | 2019-2021 | |
| Alcon Vision LLC | $404.68 | 2019-2025 | Rocklatan, Dailies Total1, Total30 |
| Novartis Pharmaceuticals Corporation | $313.06 | 2019-2023 | |
| Harrow Eye, LLC | $261.19 | 2024-2025 | Vevye |
| Glaukos Corporation | $151.67 | 2022-2025 | Photrexa Viscous and Photrexa |
| Horizon Therapeutics Plc | $119.00 | 2021-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $106.61 | 2021-2022 | |
| Optos, INC. | $105.17 | 2019 | |
| Allergan, INC. | $98.89 | 2021-2022 | |
| Carl Zeiss Meditec, INC. | $98.59 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $75.94 | 2019-2024 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $66.73 | 2024-2025 | Xdemvy |
| Amgen INC. | $58.67 | 2024 | Tepezza |
| Genentech USA, INC. | $52.74 | 2025 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $40.66 | 2020-2022 | |
| Astellas Pharma US INC | $36.33 | 2024 | Izervay |
| Dompe US, INC. | $20.07 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $19.61 | 2019 | |
| Rayner Intraocular Lenses Limited | $17.15 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Shire North American Group INC | $16.71 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $13.94 | 2021 | |
| Rxsight INC | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.